TITLE

Pain society urges FDA to modify action

PUB. DATE
September 2009
SOURCE
Hospice Management Advisor;Sep2009, Vol. 14 Issue 9, p106
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the urge of the American Pain Society (APS) for the U.S. Food and Drug Administration (FDA) to modify a restricted distribution program. In a letter to the FDA, the APS requested the agency to alter a program for the pain opioid Onsolis. The APS recommended the FDA to solicit advice from palliative care organizations to lessen the unintended results of the drug access restrictions, called risk evaluation and mitigation strategies (REMS).
ACCESSION #
43975049

 

Related Articles

  • APS 2010: opioid safety and tolerability analyses take center stage.  // PharmaWatch: CNS;Jul2010, Vol. 9 Issue 7, p19 

    Information about the topics discussed at the 2010 American Pain Society (APS Annual Meeting in the U.S. is presented. It featured the presentation of Johnson & Johnson and Grunenthal which proved the safety, tolerability and discontinuation rate of tapentadol ER over oxycodone CR. The event...

  • New Pain Drug from Snail Venom.  // Guide;Feb2005, Vol. 25 Issue 2, p78 

    Reports that the United States Food and Drug Administration has approved Prialt, a new drug for hard-to-treat pain associated with cancer, AIDS and neuropathies that may improve pain management. Comparison with morphine; Drug as an alternative to opioid drugs.

  • FDA Releases Guidance on Opioids. Haigney, Susan // BioPharm International;Feb2013, Vol. 26 Issue 2, p8 

    The article offers information on the U.S. Food and Drug Administration (FDA) regarding the release of an official document titled "Guidance for Industry: Abuse-Deterrent Opioids-Evaluation and Labeling, Draft Guidance" as its effort to help industry develop abuse-deterrent opioids.

  • FDA approves extended-release oxycodone combo to deter abuse. Chamberlin, Kevin W. // Drug Topics;Dec2014, Vol. 158 Issue 12, p64 

    The article reports that the U.S. Food & Drug Administration (FDA) approved an opioid analgesic with an abuse deterrent on July 23, 2014, for treatment of severe pain.

  • FDA review: risks of pain medicines during pregnancy.  // Reactions Weekly;Jan2015, Vol. 1535 Issue 1, p3 

    The article focuses on the move of the U.S. Food and Drug Administration to review the risks of using prescription and over-the-counter pain medicines during pregnancy.

  • FDA Panel Wants Stronger REMS for Opioids.  // BioWorld Today;7/26/2010, Vol. 21 Issue 142, p5 

    The article reports on the decision of a U.S. Food and Drug Administration (FDA) advisory panel to reject a classwide risk evaluation and mitigation strategy (REMS) plan proposed by the agency for extended-release and long-acting opioids. According to the panel, the plan was too weak to prevent...

  • New rules for opioid prescribing. Elliott, William T. // Travel Medicine Advisor;Apr2009 Pharmacology Watch, p2 

    The article reports on the plans of the U.S. Food and Drug Administration to tightened regulations on use of opioid drugs in 2009. Such drugs include fentanyl, hydromorphone and oxymorphone, among others. The move is reportedly in reaction to the misuse and abuse of these drugs as of February...

  • Guidelines for the Use of Opioid Therapy in Patients with Chronic Noncancer Pain. HUNTZINGER, AMBER // American Family Physician;12/1/2009, Vol. 80 Issue 11, p1315 

    The article focuses on a guideline for the use of opioids in patients suffering from chronic noncancer pain released by the American Pain Society and American Academy of Pain Medicine. It stresses the need for physicians and patients to discuss the risks and benefits of chronic opioid therapy...

  • Drug advisory: oxycodone hydrochloride (OxyContin). Wooltorton, Eric // CMAJ: Canadian Medical Association Journal;9/4/2001, Vol. 165 Issue 5, p624 

    Presents a United States Food and Drug Administration-issued drug advisory about the opioid oxycodone hydrochloride, or OxyContin, because of its potential for abuse. Reason for the advisory; Description and details of the drug; Suggestions for further action.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics